alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

118TH CONGRESS 

2D SESSION H. R. 7246 

To prohibit certain persons from purchasing real estate in the United States. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 6, 2024 

Mr. ALFORD (for himself, Mr. RESCHENTHALER, Mr. DESJARLAIS, Mr. 

PFLUGER, Mr. MOONEY, Mr. DUNCAN, Ms. GREENE of Georgia, and Mr. 

WEBER of Texas) introduced the following bill; which was referred to the 

Committee on Foreign Affairs 

A BILL 

To prohibit certain persons from purchasing real estate in 

the United States. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘American Land and 

5 Property Protection Act’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7246 IH

1 SEC. 2. PROHIBITION ON THE PURCHASE OF PUBLIC OR 

2 PRIVATE REAL ESTATE LOCATED IN THE 

3 UNITED STATES BY NATIONALS OF THE PEO4 PLE’S REPUBLIC OF CHINA, THE RUSSIAN 

5 FEDERATION, NORTH KOREA, IRAN, AND 

6 OTHER FOREIGN ADVERSARIES. 

7 (a) IN GENERAL.—Notwithstanding any other provi8 sion of law, the President shall take such actions as may 

9 be necessary to prohibit the purchase of public or private 

10 real estate located in the United States by nonresident 

11 aliens, foreign businesses, an agent, trustee, or fiduciary 

12 associated with the Government of the People’s Republic 

13 of China, the Government of the Russian Federation, the 

14 Government of North Korea, the Government of Iran, and 

15 the governments of other foreign adversaries. 

16 (b) DEFINITIONS.—In this section— 

17 (1) the term ‘‘foreign adversary’’ includes— 

18 (A) the People’s Republic of China, includ19 ing the Hong Kong Special Administrative Re20 gion, and excluding Taiwan; 

21 (B) the Republic of Cuba; 

22 (C) the Islamic Republic of Iran; 

23 (D) the Democratic People’s Republic of 

24 Korea; 

25 (E) the Russian Federation; 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 7246 IH

1 (F) Venezuelan politician Nicola ́s Maduro; 

2 and 

3 (G) any organization designated as a for4 eign terrorist organization by the Secretary of 

5 State pursuant to section 219 of the Immigra6 tion and Nationality Act (8 U.S.C. 1189); and 

7 (2) the term ‘‘United States’’ means the several 

8 States, the District of Columbia, the Commonwealth 

9 of Puerto Rico, the Commonwealth of the Northern 

10 Mariana Islands, American Samoa, Guam, the 

11 United States Virgin Islands, and any other terri12 tory or possession of the United States. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
EXHIBIT 31.2
 
 EXCHANGE ACT RULE 13a-14(a) CERTIFICATION
 (Principal Executive Officer)
 
 I, Thomas G. Hood, certify that:
 
 1.
I have reviewed this quarterly report on Form 10-Q of Southwall Technologies Inc.; 
 2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 
 3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 
 4.
The chief financial officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: 
 (a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
 (b)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
 (c)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 
 5.
The chief financial officer and I have disclosed, based on our most recent valuation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): 
 (a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,summarize and report financial information; and 
 (b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 11th, 2004/s/ Maury AustinMaury AustinChief Financial Officer
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM GLAMIS GOLD
LTD. CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 1999
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 10-Q.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                                    3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                          41,855
<SECURITIES>                                         0
<RECEIVABLES>                                    5,592
<ALLOWANCES>                                         0
<INVENTORY>                                     11,055
<CURRENT-ASSETS>                                60,308
<PP&E>                                         307,070
<DEPRECIATION>                                 179,481
<TOTAL-ASSETS>                                 198,650
<CURRENT-LIABILITIES>                           26,090
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       156,506
<OTHER-SE>                                     (2,612)
<TOTAL-LIABILITY-AND-EQUITY>                   198,650
<SALES>                                          7,986
<TOTAL-REVENUES>                                 7,986
<CGS>                                            7,189
<TOTAL-COSTS>                                   11,512
<OTHER-EXPENSES>                                   625
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (3,609)
<INCOME-TAX>                                     (288)
<INCOME-CONTINUING>                            (3,321)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (3,321)
<EPS-PRIMARY>                                   (0.07)
<EPS-DILUTED>                                   (0.07)
        

</TABLE>
Champion Enterprises, Inc.
Computation of Earnings Per Share

(in 000's, except per share amounts)

                               Three Months Ended    Six Months Ended
                               June 28,  June 29,   June 28,   June 29,
                                 1997      1996       1997      1996

EARNINGS

Net Income                     $18,200   $19,146     $32,039   $32,888
                               =======   =======     =======   =======  



SHARES USED FOR CALCULATING
   EARNINGS PER SHARE

Average Shares Outstanding      48,252    47,428     48,155    47,518

Additional Shares Resulting 
   from Assumed Exercise
   of Stock Options              1,235     1,980      1,425     1,807
                                ______    ______     ______    ______

Total                           49,487    49,408     49,580    49,325
                                ======    ======     ======    ======


PER SHARE AMOUNTS

Net Income                       $0.37     $0.39     $0.65     $0.67
                                 =====     =====     =====     =====




NOTE:  This calculation is submitted in accordance with Securities and
Exchange Act of 1934 Release No. 9083.
###### Editorial Note on Part 72

#### Editorial Note:

Nomenclature changes to part 72 appear at 80 FR 74981, Dec. 1, 2015, and at 81 FR 86910, Dec. 2, 2016.

#### § 72.18 Elimination of repetition.

In any application under this part, the applicant may incorporate by reference information contained in previous applications, statements, or reports filed with the Commission: Provided, That such references are clear and specific.
Denied Order Entered September 22, 2021

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-21-00219-CV

IN RE TEKIN & ASSOCIATES, LLC, Relator

Original Proceeding from the County Court at Law No. 2

Dallas County, Texas

Trial Court Cause No. CC-20-01986-B

ORDER

Before Justices Osborne, Pedersen, III, and Goldstein

Based on the Court’s opinion of this date, we DENY relator’s petition for 

writ of mandamus. 

/Bill Pedersen, III//

BILL PEDERSEN, III

JUSTICE
<PAGE>   1
                                                                    Exhibit 99.2


RELEASE 98-6

POPE & TALBOT ANNOUNCES SUCCESSFUL ACQUISITION OF HARMAC PACIFIC

For Release at 8:00 a.m. EST- January 30, 1998

     PORTLAND, OR -- Pope & Talbot, Inc. through its indirect wholly-owned
Canadian subsidiary Pope & Talbot Pulp Ltd. has been informed by the Depositary
under its Offer to Purchase 6,450,000 common shares of Harmac Pacific Inc. dated
December 20, 1997 that approximately 7,640,000 common shares of Harmac Pacific
were tendered to the Depository prior to the expiry time.

     Pope & Talbot exercised its option pursuant to the terms of the Offer to
acquire the maximum number of shares which represents, together with the
1,648,700 shares already owned by the Company's subsidiary, Pope & Talbot Ltd.,
53.5% of the common shares outstanding of Harmac Pacific.

     Pope & Talbot advised the Depository that all conditions specified in the
Offer have been satisfied or are waived and that the Company will take-up and
pay for 6,764,759 common shares tendered on a prorata basis, disregarding
fractions, according to the number of shares deposited by each shareholder by
the expiry time on January 29, 1998. The payment date will be February 2, 1998.

     As stated in the Offer, Pope & Talbot has been seeking a controlling
interest in Harmac Pacific and intends to request certain changes including the
composition of Harmac Pacific's Board of Directors.

     "We are very pleased with the outcome" said Peter T. Pope, Chairman and
Chief Executive Officer of Pope & Talbot. "We are impressed with Harmac's
product quality, its management and marketing organization, and we believe that
with Pope & Talbot's operating experience, Harmac can be an even better company
in the future. Furthermore, we believe that Harmac forms the basis for a
consolidation of the North American kraft pulp industry."

     Pope & Talbot, Inc. is an integrated wood-fiber products company that is
focused on the production of softwood lumber and kraft pulp. The Company was
founded in 1849, is headquartered in Portland, Oregon and currently operates
three sawmills in the Southern interior of British Columbia.

     Goepel Shields & Partners Inc. acted as financial advisors to Pope & Talbot
in this transaction.


                                       ###
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7397 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7397

    To amend title XVIII of the Social Security Act to establish a 
           definition of essential health system in statute.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 15, 2024

  Mrs. Trahan (for herself and Mr. Valadao) introduced the following 
  bill; which was referred to the Committee on Ways and Means, and in 
 addition to the Committee on Energy and Commerce, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL

 
    To amend title XVIII of the Social Security Act to establish a 
           definition of essential health system in statute.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ESTABLISHING A DEFINITION OF ESSENTIAL HEALTH SYSTEM IN 
              STATUTE.

    Section 1861 of the Social Security Act (42 U.S.C. 1395x) is 
amended by adding at the end the following new subsection:
    ``(nnn) Essential Health System.--The term `essential health 
system' means a hospital--
            ``(1) that is a subsection (d) hospital (as defined in 
        section 1886(d)(1)(B));
            ``(2) that is a non-Federal governmental or private 
        nonprofit hospital; and
            ``(3) that--
                    ``(A) meets the requirements of a Medicaid deemed 
                disproportionate share hospital (as described in 
                section 1923(b)(1));
                    ``(B) has a Medicare disproportionate patient 
                percentage of at least 35 percent (as defined in 
                section 1886(d)(5)(F)(vi)); or
                    ``(C) has a Medicare disproportionate share 
                hospital uncompensated care payment factor of 0.0005 or 
                more, (as defined in section 1886(r)(2)(C)).''.
                                 <all>
```
§ 310.527 Drug products containing active ingredients offered over-the-counter (OTC) for external use as hair growers or for hair loss prevention. ( a ) Amino acids, aminobenzoic acid, ascorbic acid, benzoic acid, biotin and all other B-vitamins, dexpanthenol, estradiol and other topical hormones, jojoba oil, lanolin, nucleic acids, polysorbate 20, polysorbate 60, sulfanilamide, sulfur 1 percent on carbon in a fraction of paraffinic hydrocarbons, tetracaine hydrochloride, urea, and wheat germ oil have been marketed as ingredients in OTC drug products for external use as hair growers or for hair loss prevention. There is a lack of adequate data to establish general recognition of the safety and effectiveness of these or any other ingredients intended for OTC external use as a hair grower or for hair loss prevention. Based on evidence currently available, all labeling claims for OTC hair grower and hair loss prevention drug products for external use are either false, misleading, or unsupported by scientific data. Therefore, any OTC drug product for external use containing an ingredient offered for use as a hair grower or for hair loss prevention cannot be considered generally recognized as safe and effective for its intended use.
( b ) Any OTC drug product that is labeled, represented, or promoted for external use as a hair grower or for hair loss prevention is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act), for which an approved new drug application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application, such product is also misbranded under section 502 of the act.
( c ) Clinical investigations designed to obtain evidence that any drug product labeled, represented, or promoted for OTC external use as a hair grower or for hair loss prevention is safe and effective for the purpose intended must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.
( d ) After January 8, 1990, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.
[54 FR 28777, July 7, 1989]
H. Res. 411 

In the House of Representatives, U. S., 

June 27, 2017. 

Whereas on June 14, 2017, an armed gunman opened fire 

at a practice for the annual Congressional Baseball Game 

for Charity, wounding five individuals; 

Whereas Members of the House are understandably concerned about the security of their staff and the constituents they serve, as well as their personal security; 

Whereas the Members’ Representational Allowance (MRA) is 

available for ordinary and necessary expenses associated 

with security measures; and 

Whereas heightened security concerns necessitate an adjustment in the MRA to provide Members with additional resources: Now, therefore, be it 

Resolved, That pursuant to section 1(b) of House Resolution 1372, Ninety-fourth Congress, agreed to July 1, 1976, 

as enacted into permanent law by section 101 of the Legislative Branch Appropriation Act, 1977 (2 U.S.C. 4314), the 

Members’ Representational Allowance applicable as of the 

date of the adoption of this resolution for each Member of 

the House of Representatives (including the Delegates and 
2 

•HRES 411 EH 

Resident Commissioner to the Congress) is increased by 

$25,000, to be available through January 2, 2018. 

Attest: 

Clerk.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1415 Animal lipase. ( a ) Animal lipase (CAS Reg. No. 9001-62-1) is an enzyme preparation obtained from edible forestomach tissue of calves, kids, or lambs, or from animal pancreatic tissue. The enzyme preparation may be produced as a tissue preparation or as an aqueous extract. Its characterizing enzyme activity is that of a triacylglycerol hydrolase (EC 3.1.1.3).
( b ) The ingredient meets the general requirements and additional requirements for enzyme preparations in the Food Chemicals Codex, 3d ed. (1981), p. 110, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, 2101 Constitution Ave., NW., Washington, DC 20418, or may be examined at the Office of Food Additive Safety (HFS-200), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-1200, and at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as GRAS as a direct food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an enzyme as defined in § 170.3(o)(9) of this chapter to hydrolyze fatty acid glycerides.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
[60 FR 32911, June 26, 1995, as amended at 78 FR 14666, Mar. 7, 2013]
### Methods and applications of electrical simulation in ground-water studies in the lower Arkansas and Verdigris River Valleys, Arkansas and Oklahoma

By: M. S. BedingerJ. E. ReedC.J. WellsB.F. Swafford

                            https://doi.org/10.3133/wsp1971

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf)
  - **Plate 3**                            (pdf)
  - **Plate 4**                            (pdf) 
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
* Pursuant to 5TH CIR. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 96-40997

Summary Calendar

 

EDDIE TYLER,

Plaintiff-Appellant,

versus

WAYNE SCOTT, Director,

Texas Department of Criminal Justice,

Institutional Division; L. WOODS, Warden;

D. STARK, Doctor; O. CISNEROS; L. EASON,

Defendants-Appellees.

- - - - - - - - - -

Appeal from the United States District Court

for the Southern District of Texas

USDC No. C-96-CV-347

- - - - - - - - - -

August 8, 1997

Before POLITZ, Chief Judge, KING and SMITH, Circuit Judges.

PER CURIAM:*

Texas prisoner Eddie Tyler, No. 535926, appeals the

dismissal of his suit pursuant to 28 U.S.C. § 1915(e)(2)(B)(i). 

Tyler argues that the defendants were deliberately indifferent to

his serious medical need and that they conspired to retaliate

against him. We have reviewed the record and Tyler’s brief and

find no evidence of deliberate indifference to a serious medical
No. 96-40997

-2-

need. See Mendoza v. Lynaugh, 989 F.2d 191, 193-94 (5th Cir.

1993); Jackson v. Cain, 864 F.2d 1235, 1246 (5th Cir. 1989). 

Tyler’s conclusional allegations that the defendants conspired to

retaliate against him fail to state a claim under 42 U.S.C. 

§ 1983. Babb v. Dorman, 33 F.3d 472, 476 (5th Cir. 1994).

Tyler has moved the court for a preliminary injunction;

filed four motions to supplement his appellate brief; and

requested that the court appoint appellate counsel, order entry

of his exhibits, and allow “final arguments.” He asks that a

panel of the court review his x-rays, and he has filed a motion

concerning jurisdiction which does not request any form of

relief. The foregoing motions are DENIED.

AFFIRMED. MOTIONS DENIED.
#### § 516.16 Eligibility to request designation.

The person requesting designation must be the sponsor and the real party in interest of the development and the intended or actual production and sales of the drug or the permanent-resident U.S. agent for such a sponsor.